

# Anti-VEGF Reference Antibody (BioMab patent anti-VEGF)

Recombinant Antibody

Catalog # APR10217

## Product Information

---

<b>Application</b>	FC, Kinetics, Animal Model
<b>Primary Accession</b>	<a href="#">P15692</a>
<b>Reactivity</b>	Human, Mouse
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1
<b>Calculated MW</b>	43597

## Additional Information

---

<b>Target/Specificity</b>	VEGF
<b>Endotoxin</b>	
<b>Conjugation</b>	Unconjugated
<b>Expression system</b>	CHO Cell
<b>Format</b>	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.


## Protein Information

---


<b>Name</b>	VEGFA
<b>Synonyms</b>	VEGF
<b>Function</b>	[N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed: <a href="#">35455969</a> ). Involved in protecting cells from hypoxia- mediated cell death (By similarity).
<b>Cellular Location</b>	[N-VEGF]: Cytoplasm. Nucleus. Note=Cytoplasmic in normoxic conditions and localizes to the nucleus under hypoxic conditions [Isoform L-VEGF189]: Endoplasmic reticulum. Golgi apparatus. Secreted, extracellular space, extracellular matrix [Isoform VEGF165]: Secreted
<b>Tissue Location</b>	Higher expression in pituitary tumors than the pituitary gland. [Isoform VEGF165]: Widely expressed. [Isoform VEGF206]: Not widely expressed.

## Images


---




Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) is more than 97.8%, determined by SEC-HPLC.



Immobilized human VEGF165 His at 2 µg/mL can bind Anti-VEGF Reference Antibody (BioMab patent anti-VEGF),  $EC_{50}=0.003018$  µg/mL



Bevacizumab inhibited the tumor growth of COLO205 on balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 42.0% at 0.95 mpk at D31.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.